Imovane (Zopiclone)

Zopiclone binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This enhances the inhibitory effect of GABA, increasing chloride ion flow into neurons, which reduces neuronal excitability and produces a sedative‑hypnotic effect.

The dose of Imovane is individualized by the prescribing clinician based on the patient’s age, renal function, and overall health. Typical adult dosing ranges from 3.75 mg to 7.5 mg taken shortly before bedtime, but the exact regimen must be determined by a qualified healthcare professional.

Safety data for Zopiclone in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Imovane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

The primary alternative to Zopiclone is the benzodiazepine class, such as temazepam. While both promote sleep, Zopiclone is a cyclopyrrolone with a slightly different receptor binding profile, often associated with a lower risk of next‑day sedation. However, both agents carry potential for dependence and should be used for short periods.

Imovane tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight. Do not use the product if the packaging is damaged or the tablets appear discoloured.

Imovane is taken orally as a tablet with a glass of water. It should be taken shortly before bedtime, and patients should ensure they have a full night (7–8 hours) of sleep opportunity. The tablet should be swallowed whole and not crushed or chewed.

Serious risks include complex sleep behaviours such as sleepwalking or sleep‑driving, severe allergic reactions, respiratory depression (especially when combined with other depressants), and the potential for dependence or withdrawal symptoms after prolonged use. Patients should seek immediate medical attention if any of these occur.

Imovane is contraindicated in individuals with known hypersensitivity to Zopiclone or any excipients, severe hepatic or renal impairment, untreated severe sleep apnea, and in patients who are pregnant or breastfeeding unless the benefit outweighs the risk. Caution is also advised for those with a history of substance misuse.